Quantitative Hepatitis B surface antigen in different phases of Vietnamese chronic HBV infected patients

In Denmark, universal screening of pregnant women for hepatitis B has been in place since November 2005, with the first two years as a trial period with enhanced surveillance. It is unknown what the change to universal screening without enhanced surveillance has meant for vaccination coverage among children born to hepatitis B surface antigen (HBsAg)-positive mothers and what risk factors exist for incomplete vaccination. This retrospective cohort study included 699 children of mothers positive for HBsAg. Information on vaccination and risk factors was collected from central registers. In total, 93% (651/699) of the children were vaccinated within 48 hours of birth, with considerable variation between birthplaces. Only 64% (306/475) of the children had received all four vaccinations through their general practitioner (GP) at the age of two years, and 10% (47/475) of the children had received no hepatitis B vaccinations at all. Enhanced surveillance was correlated positively with coverage of birth vaccination but not with coverage at the GP. No or few prenatal examinations were a risk factor for incomplete vaccination at the GP. Maternity wards and GPs are encouraged to revise their vaccination procedures and routines for pregnant women, mothers with chronic HBV infection and their children.

Download Full-text

Hepatitis B Surface Antigen level and its Correlation with Age, Gender, and Liver Biomarkers

Research Journal of Pharmacy and Technology ◽

10.52711/0974-360x.2021.00729 ◽

2021 ◽

pp. 4207-4211

Author(s):

Zainab A. Hamid ◽

M. Sc Yasmeen J. Al-Bayaa ◽

Ali Hattem Hussain

Keyword(s):

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Correlation Coefficients ◽

Total Serum ◽

Age Group ◽

Patients Âgés ◽

Positive Hbsag ◽

Chronic Hbv ◽

The Mean

Background: Measuring the concentration of hepatitis B surface antigen (HbsAg) in HBV patients can be determined with immunoassay techniques. This study aimed to measure the HbsAg titers in chronic HBV patients and to assess its correlation with patients' ages, gender, and with the levels of liver enzymes and total serum bilirubin. Materials and Method: Fifty-eight chronic hepatitis B infected patients were enrolled in this study. Age and gender of the patients were recorded. HbsAg concentration was tested with automated Immunoanalyzer. The patients were also tested for ALT, AST, ALP, and TSB by automated chemistry analyzer. Results: All the chronic HBV patients have positive HBsAg titers above the negative cutoff (0.05U/L) with mean concentration equal to 3099.7U/L, and a range of 0.25-6005.2 U/L. The highest mean HbsAg concentration was in age group 50-59, while the least was in age group ≥60. There was weak negative insignificant correlation between HbsAg concentrations and ages of patients. Thirty one of the patients were males and 27 were females. The means of HbsAg concentrations between males and females were statistically not significant. The mean ALT concentration was 60.038U/L, for AST was 40.728U/L, for ALP was 113.722 U/L, and for TSB was 1.168mg/dl. The values of correlation coefficients (R) between HBsAg titers and the concentrations of ALT, AST, ALP, and TSB were 0.13, 0.11, 0.12, and 0.14, respectively. Conclusions: The HBsAg titers are positive among all chronic HBV patients, with a mean titer of 3099.7U/L and all of the values are below 10000.0U/L. The mean titers increase gradually with age to reach the peak in age group 50-59 years old then decline The age, gender, serum ALT, serum AST, serum ALP, and TSB all have weak insignificant correlations with HBsAg titers among chronic HBV patients. The serum ALT is the most commonly elevated liver biomarker in chronic HBV patients.

Download Full-text

Functional implications of hepatitis B surface antigen (HBsAg) in the T cells of chronic HBV carriers

Journal of Viral Hepatitis ◽

10.1046/j.1365-2893.1997.00056.x ◽

1997 ◽

Vol 4 (4) ◽

pp. 221-230 ◽

Cited By ~ 6

Author(s):

K. Nagaraju ◽

S. R. Naik ◽

S. Naik

Keyword(s):

T Cells ◽

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Functional Implications ◽

Chronic Hbv

Download Full-text

Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection

Antiviral Therapy ◽

10.3851/imp1637 ◽

2010 ◽

Vol 15 (6) ◽

pp. 887-895 ◽

Cited By ~ 19

Author(s):

Sheikh Mohammad Fazle Akbar ◽

Osamu Yoshida ◽

Shiyi Chen ◽

Aguilar Julio Cesar ◽

Masanori Abe ◽

...

Keyword(s):

Dendritic Cells ◽

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Hbv Infection ◽

Core Antigen ◽

Chronic Hbv Infection ◽

Immune Modulator ◽

Chronic Hbv

Download Full-text

Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients

The Journal of Infectious Diseases ◽

10.1093/infdis/jiaa614 ◽

2020 ◽

Author(s):

Noé R Montanari ◽

Nádia Conceição-Neto ◽

Ilse Van Den Wyngaert ◽

Gertine W Van Oord ◽

Zwier M A Groothuismink ◽

...

Keyword(s):

Gene Expression ◽

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Inactive Carrier ◽

B Virus ◽

Infected Liver ◽

Differential Gene ◽

Chronic Hbv

Abstract Long-term viremia control in chronic HBV patients occurs either spontaneously in inactive carrier (IC) patients or therapy-induced by nucleos(t)ide analogues (NUC). To better understand the characteristics of viremia control, we evaluated gene expression in purified leukocyte subsets from IC versus NUC-treated patients, and evaluated the putative modulatory effects of hepatitis B surface antigen (HBsAg). We observed that gene expression in NUC-treated patients differed markedly from IC patients, especially in dendritic cells, monocytes, and CD8+ T cells, while serum HBsAg levels had little effect. Nevertheless, based on our findings it cannot be excluded that HBsAg may act locally in the infected liver or preferentially affects HBV-specific cells.

Download Full-text

Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers

Annals of Hepatology ◽

10.5604/01.3001.0010.8640 ◽

2018 ◽

Vol 17 (2) ◽

pp. 232-241 ◽

Cited By ~ 2

Author(s):

Conar R. O’Neil ◽

Stephen E. Congly ◽

M. Sarah Rose ◽

Samuel S. Lee ◽

Meredith A. Borman ◽

...

Keyword(s):

Hepatitis B ◽

Surface Antigen ◽

North American ◽

Hepatitis B Surface Antigen ◽

Long Term Follow Up ◽

Chronic Hbv

Download Full-text

Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation

Gut ◽

10.1136/gutjnl-2020-321116 ◽

2020 ◽

pp. gutjnl-2020-321116 ◽

Cited By ~ 3

Author(s):

Wai-Kay Seto ◽

Kevin SH Liu ◽

Lung-Yi Mak ◽

Gavin Cloherty ◽

Danny Ka-Ho Wong ◽

...

Keyword(s):

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Hbv Dna ◽

Treatment Cessation ◽

Serum Hbsag ◽

Median Serum ◽

Hbsag Seroclearance ◽

Chronic Hbv

BackgroundTreatment cessation in chronic HBV infection may be durable in certain patient subgroups before hepatitis B surface antigen (HBsAg) seroclearance. The role of serum HBV RNA in determining treatment cessation suitability has not been well-investigated.MethodsNucleos(t)ide analogue (NUC) treatment was discontinued in non-cirrhotic patients with chronic HBV with serum HBsAg <200 IU/mL and fulfilling internationally recommended criteria for treatment cessation. Patients were monitored till 48 weeks with baseline and serial measurements of serum HBsAg, HBV RNA and hepatitis B core-related antigen. NUCs were resumed when HBV DNA reaches >2000 IU/mL regardless of alanine aminotransferase (ALT) levels.Results114 entecavir-treated patients (median age 58.4 years, median serum HBsAg 54.4 IU/mL) with median treatment duration of 6.7 years were recruited. The 48-week cumulative rate of HBV DNA >2000 IU/mL was 58.1%. End-of-treatment serum HBV RNA and off-treatment serial HBV RNA were both independently associated with HBV DNA >2000 IU/mL (HR 2.959, 95% CI 1.776 to 4.926, p<0.001; HR 2.278, 95% CI 1.151 to 4.525, p=0.018, respectively). Patients with HBV RNA ≥44.6 U/mL had a cumulative 48-week rate of 93.2%, while combining HBV RNA undetectability and HBsAg <10 IU/mL had a cumulative 48-week rate of 9.1%. 24 patients (38.7%) developed off-treatment ALT elevation, highest peak ALT was 1515 U/L. 8 patients (median serum HBsAg 2.6 IU/mL) developed HBsAg seroclearance.ConclusionSerum HBV RNA measurement is essential for deciding on entecavir cessation in patients with chronic HBV, especially with low HBsAg levels. Patients can be stratified on their risk of off-treatment relapse based on both viral determinants.Trial registration numberNCT02738554

Download Full-text